Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Identix (IDNX) -- Ignore unavailable to you. Want to Upgrade?

To: Ed Flynn who wrote (11537)	12/2/1998 5:04:00 PM
From: David	Read Replies (1) \| Respond to of 26039

Sensar uses Iriscan patents. So I think controlling Iriscan is a good way of controlling the iris-ID market (which has got to be pretty small at this point). Sensar has just gotten $28 million in financing from a group that includes Citigroup, J.P. Morgan & Co., NCR, Lehman Bros. and a unit of Merrill Lynch. As to cost, I believe this technology is expensive, maybe on the order of $2,000 per unit (just from memory, so I could be wrong). Perhaps the new investors are trying to bring down unit costs. Eye scanning has some advantages in ATMs over fingerscanning, but I don't think, generally, that it has as many useful applications as fingerprints.